TR201820411T4 - Rasetam ve karnitin içeren farmasötik bileşim ve bunun hazırlanış süreci. - Google Patents

Rasetam ve karnitin içeren farmasötik bileşim ve bunun hazırlanış süreci. Download PDF

Info

Publication number
TR201820411T4
TR201820411T4 TR2018/20411T TR201820411T TR201820411T4 TR 201820411 T4 TR201820411 T4 TR 201820411T4 TR 2018/20411 T TR2018/20411 T TR 2018/20411T TR 201820411 T TR201820411 T TR 201820411T TR 201820411 T4 TR201820411 T4 TR 201820411T4
Authority
TR
Turkey
Prior art keywords
pharmaceutical composition
racetam
carnitine
composition containing
preparation process
Prior art date
Application number
TR2018/20411T
Other languages
English (en)
Inventor
Roberto Da Costa Perreira José
Falci Marcio
Matteis Alario Mauricio
Original Assignee
Biolab Sanus Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolab Sanus Farmaceutica Ltda filed Critical Biolab Sanus Farmaceutica Ltda
Publication of TR201820411T4 publication Critical patent/TR201820411T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut buluş rasetam ve karnitin içeren farmasötik bir bileşimle ilgidir. Söz konusu farmasötik bileşim ayrıca koenzim Q10 ve/veya statin grubunun hipokolesterolemik ajanı, bir hipoglisemik ajan ya da bir antiepileptik ajan gibi mitokondriyal ve/veya metabolik rahatsızlıkla ilişkili ajanı içerebilir. Buluş ayrıca mitokondriyal rahatsızlıkların tedavisi için buluşun farmasötik bileşiminin verilmesini içeren bir metotla da ilgilidir.
TR2018/20411T 2008-02-29 2009-02-27 Rasetam ve karnitin içeren farmasötik bileşim ve bunun hazırlanış süreci. TR201820411T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0800432 2008-02-29

Publications (1)

Publication Number Publication Date
TR201820411T4 true TR201820411T4 (tr) 2019-01-21

Family

ID=41016503

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/20411T TR201820411T4 (tr) 2008-02-29 2009-02-27 Rasetam ve karnitin içeren farmasötik bileşim ve bunun hazırlanış süreci.

Country Status (20)

Country Link
US (1) US20110052556A1 (tr)
EP (1) EP2262495B1 (tr)
JP (1) JP5677856B2 (tr)
KR (1) KR101686917B1 (tr)
CN (1) CN102014896A (tr)
AR (1) AR070713A1 (tr)
AU (1) AU2009219050B2 (tr)
CA (1) CA2716020C (tr)
CL (1) CL2009000478A1 (tr)
CO (1) CO6400019A1 (tr)
ES (1) ES2699458T3 (tr)
HU (1) HUE042168T2 (tr)
IL (1) IL207852A (tr)
MX (1) MX2010009290A (tr)
PE (1) PE20091564A1 (tr)
PL (1) PL2262495T3 (tr)
PT (1) PT2262495T (tr)
TR (1) TR201820411T4 (tr)
WO (1) WO2009105853A2 (tr)
ZA (1) ZA201006031B (tr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102525899B (zh) * 2012-01-17 2013-04-17 山东罗欣药业股份有限公司 一种奥拉西坦组合物注射液及其制备方法
CN103099211A (zh) * 2012-12-21 2013-05-15 洪万雄 一种融合辅酶q10的广谱性一氧化氮保健品
LV15003B (lv) * 2013-10-22 2015-08-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
CN108853029A (zh) * 2018-09-07 2018-11-23 南通雅本化学有限公司 一种罗苏伐他汀的制备方法
US20240050406A1 (en) * 2021-04-26 2024-02-15 Ksb Tugen Inc. Composition comprising oxiracetam for preventing or treating muscular disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
DE69001146T2 (de) * 1989-01-18 1993-10-07 Merck & Co Inc Koenzym Q10 mit HMG-COA-Reduktase-Inhibitoren.
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
IT1293067B1 (it) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico
WO2000074675A1 (en) * 1999-06-08 2000-12-14 Sigma-Tau Industrie Farmaceutiche S.P.A. Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
JP4970692B2 (ja) 2000-05-09 2012-07-11 株式会社カネカ 動脈硬化抑制方法及び組成物
US20020058026A1 (en) 2000-11-13 2002-05-16 Milton Hammerly HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10
AUPR177300A0 (en) 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1613590A2 (en) * 2003-04-16 2006-01-11 Memory Pharmaceutical Corporation 4-(3,4-disubstituted phenyl)-pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US20090298864A1 (en) * 2005-04-11 2009-12-03 The Trustees Of Columbia University In The City Of New York Methods for Treating Mild Cognitive Impairment
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress

Also Published As

Publication number Publication date
US20110052556A1 (en) 2011-03-03
PL2262495T3 (pl) 2019-03-29
AU2009219050B2 (en) 2014-04-24
JP2011513246A (ja) 2011-04-28
CA2716020C (en) 2018-10-16
KR20100126454A (ko) 2010-12-01
PE20091564A1 (es) 2009-11-04
PT2262495T (pt) 2019-02-04
EP2262495A4 (en) 2012-01-11
AU2009219050A1 (en) 2009-09-03
CA2716020A1 (en) 2009-09-03
EP2262495B1 (en) 2018-10-31
KR101686917B1 (ko) 2016-12-15
CO6400019A1 (es) 2012-03-15
WO2009105853A2 (en) 2009-09-03
AR070713A1 (es) 2010-04-28
CL2009000478A1 (es) 2009-08-07
JP5677856B2 (ja) 2015-02-25
ES2699458T3 (es) 2019-02-11
IL207852A0 (en) 2010-12-30
IL207852A (en) 2015-07-30
MX2010009290A (es) 2010-09-14
WO2009105853A8 (en) 2010-02-18
CN102014896A (zh) 2011-04-13
HUE042168T2 (hu) 2019-06-28
EP2262495A2 (en) 2010-12-22
ZA201006031B (en) 2012-01-25
WO2009105853A3 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
TN2010000125A1 (en) Substituted biphenyl gpr40 modulators
WO2010045258A3 (en) Spirocyclic gpr40 modulators
MY148496A (en) Dpp iv inhibitor formulations
MX2007014920A (es) Politerapia que comprende diarilureas para el tratamiento de enfermedades.
BRPI0908421B8 (pt) solução estável de um composto farmacêutico
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
TW200745003A (en) Novel compounds
BR112015008297A2 (pt) antagonistas de mglu2/3 para o tratamento de distúrbios autistas
MY160249A (en) Fatty acid fumarate derivatives and their uses
ECSP088854A (es) Moduladores bencimidazolicos de vr1
TW200612892A (en) Novel compounds
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
IL190951A0 (en) Method of acting upon organism by targeted delivery of biologicaly active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
MX2010009654A (es) Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
BR112014018027A8 (pt) Composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn
TW200732296A (en) Novel compounds
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
HK1154777A1 (en) Lipoprotein lipase-activating compositions comprising benzene derivatives
ATE425961T1 (de) Salze substituierter allophansaureester und deren verwendung in arzneimitteln
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
TR201820411T4 (tr) Rasetam ve karnitin içeren farmasötik bileşim ve bunun hazırlanış süreci.
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
BRPI0621347B8 (pt) composição farmacêutica para aumentar a produção de eritrócitos e para o tratamento de anemia